Imperva (NASDAQ:IMPV) was upgraded by equities research analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a report released on Thursday, MarketBeat reports.

Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Imperva from a “hold” rating to a “sell” rating in a report on Friday, August 3rd. DA Davidson set a $56.00 price objective on shares of Imperva and gave the company a “hold” rating in a research report on Thursday. Evercore ISI reiterated a “hold” rating and set a $55.75 price objective on shares of Imperva in a research report on Thursday. Stephens lifted their price objective on shares of Imperva from $61.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, June 14th. Finally, Stifel Nicolaus reduced their price objective on shares of Imperva from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, July 27th. Eleven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $56.37.

Shares of NASDAQ:IMPV opened at $55.36 on Thursday. Imperva has a 1-year low of $37.17 and a 1-year high of $57.65. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -197.71 and a beta of 1.72.

Imperva (NASDAQ:IMPV) last issued its quarterly earnings results on Thursday, July 26th. The software maker reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.07. Imperva had a negative net margin of 8.59% and a negative return on equity of 6.92%. The business had revenue of $84.80 million for the quarter, compared to the consensus estimate of $87.22 million. During the same quarter in the previous year, the firm earned $0.24 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. As a group, equities research analysts forecast that Imperva will post -1.15 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can raised its position in shares of Imperva by 21.1% during the third quarter. Bank of Montreal Can now owns 41,778 shares of the software maker’s stock valued at $1,940,000 after buying an additional 7,268 shares during the last quarter. United Services Automobile Association increased its position in Imperva by 5.0% in the second quarter. United Services Automobile Association now owns 49,973 shares of the software maker’s stock worth $2,411,000 after purchasing an additional 2,400 shares during the last quarter. Northern Trust Corp increased its position in Imperva by 4.6% in the second quarter. Northern Trust Corp now owns 433,433 shares of the software maker’s stock worth $20,913,000 after purchasing an additional 19,224 shares during the last quarter. Bank of New York Mellon Corp increased its position in Imperva by 7.0% in the second quarter. Bank of New York Mellon Corp now owns 159,349 shares of the software maker’s stock worth $7,689,000 after purchasing an additional 10,461 shares during the last quarter. Finally, Bank of Nova Scotia bought a new stake in Imperva in the second quarter worth $3,329,000. Hedge funds and other institutional investors own 99.99% of the company’s stock.

About Imperva

Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.

Recommended Story: What is a Call Option?

Analyst Recommendations for Imperva (NASDAQ:IMPV)

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.